Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05499234 |
Other study ID # |
KARAASLANP |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
August 1, 2022 |
Est. completion date |
October 18, 2023 |
Study information
Verified date |
February 2024 |
Source |
Medipol University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The dural epidural tap method is performed by creating a dural perforation with a spinal
needle placed through epidural needle, followed by placement of a catheter into the epidural
space. No medications are administered through spinal needle. This prospective, randomized
study includes 70 ASA II primigravid women with cervical dilatation between 4-6 cm and
demanding epidural analgesia during spontaneous vaginal delivery.In the first group, 20 mL of
0.125% bupivacaine + 2 mcg/mL fentanyl solution and in the second group, 20 mL of 0.0625%
bupivacaine + 2 mcg/mL fentanyl solution was administered as the first dose through the
epidural catheter. Then, the visual analog scale (VAS) score was aimed to be below 4 in both
groups.
Description:
This prospective, randomized study includes 70 ASA II primigravid women with cervical
dilatation between 4-6 cm and demanding epidural analgesia during spontaneous vaginal
delivery. Participants with pregnancy-related diseases (such as gestational hypertension,
gestational diabetes, preeclampsia) and contraindications for neuraxial block (infection,
coagulation disorder, severe hypovolemia, sepsis, neurological deficit, cardiac valve
stenosis or hypertrophic obstructive cardiomyopathy) will be excluded from the study. Women
with fetal malpresentation and fetal anomaly will also be excluded.
Participants will randomly be divided into 2 equal groups. Immediately before epidural
placement, subjects will be marked a VAS score during an active contraction. All subjects
will have an intravenous catheter placed and be monitored with NST, noninvasive blood
pressure and pulse oximetry.
The epidural space will be identified by a loss of resistance technique to saline. CSF flow
will be observed at L3-L4 or L4-L5 level by puncturing the dura with a 27 G needle before
inserting the epidural catheter. A combined spinal epidural set with 18 G Tuohy needle will
be used in both groups. In the first group, 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl
solution and in the second group, 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution
will be administered as the first dose through the epidural catheter. Then, the visual analog
scale (VAS) score will be aimed to be below 4 in both groups. Patients with a VAS score of 4
or higher 15 minutes after the first dose received, an additional 10 mL dose of the same
solution will be given. An additional 10 mL dose also will be administered when the VAS score
is 4 or higher until crowning.
Before the epidural catheter placed; age, weight, height, blood pressure of the participants,
gestational week, use of oxytocin during delivery, cervical dilatation amount before the
procedure and fetal heart rate will be recorded. After each dose of administration, whether
maternal hypotension, fetal bradycardia, pruritus, nausea-vomiting or motor block development
will be monitored. The total amount of drug administered through the epidural catheter, the
time between applications, and the number of bolus doses administered will also be recorded.